Mcdonald Partners LLC Has $2.57 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mcdonald Partners LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 27,816 shares of the biopharmaceutical company's stock after selling 4,581 shares during the period. Mcdonald Partners LLC's holdings in Gilead Sciences were worth $2,569,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in GILD. HHM Wealth Advisors LLC increased its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares during the period. nVerses Capital LLC bought a new position in Gilead Sciences during the third quarter valued at about $25,000. YANKCOM Partnership bought a new position in Gilead Sciences during the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences during the fourth quarter valued at about $29,000. Finally, Valued Wealth Advisors LLC increased its stake in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 161 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 0.1 %

GILD stock traded down $0.08 during trading on Friday, hitting $109.95. The company had a trading volume of 9,729,048 shares, compared to its average volume of 7,379,648. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average price of $95.41 and a 200-day moving average price of $88.63. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $111.03. The stock has a market cap of $137.03 billion, a price-to-earnings ratio of 297.16, a PEG ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's payout ratio is 832.43%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GILD. The Goldman Sachs Group boosted their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the company from $80.00 to $120.00 in a research note on Tuesday. UBS Group boosted their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Finally, Mizuho lifted their price objective on Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $102.08.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares of the company's stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 713,000 shares of company stock worth $67,945,181 in the last quarter. Insiders own 0.16% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.